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Highlights  
 Flatter mean diurnal cortisol slope in patients compared to healthy controls  
 Differences in mean diurnal cortisol slope depending on severity of breathlessness 
 Positive correlation for diurnal cortisol slope and MRC dyspnoea grade in patients  
 Aberrant cortisol profile patterns in patients with moderate-to-severe breathlessness  
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Abstract 
Chronic breathlessness is a common source of psychological and physical stress in patients with 
advanced or progressive disease, suggesting that hypothalamic-pituitary-adrenal (HPA) axis 
dysregulation may be prevalent. The aim of this study was to measure the salivary diurnal cortisol 
profile in patients receiving supportive and palliative care for a range of malignant and non-
malignant conditions and to compare the profile of those experiencing moderate-to-severe disability 
due to breathlessness against that of patients with mild/no breathlessness and that of healthy 
controls. Saliva samples were collected over two consecutive weekdays at 3, 6, and 12 hours after 
awakening in 49 patients with moderate-to-severe breathlessness [Medical Research Council (MRC) 
dyspnoea grade ≥3], 11 patients with mild/no breathlessness (MRC dyspnoea grade ≤2), and 50 
healthy controls. Measures of breathlessness, stress, anxiety, depression, wellbeing and sleep were 
examined concomitantly. The diurnal cortisol slope (DCS) was calculated for each participant by 
regressing log-transformed cortisol values against collection time. Mean DCS was compared across 
groups using ANCOVA. Individual slopes were categorised into one of four categories: consistent 
declining, consistent flat, consistent ascending and inconsistent. Controlling for age, gender and 
socioeconomic status, the mean DCS was significantly flatter in patients with moderate-to-severe 
breathlessness compared to patients with mild/no breathlessness and healthy controls [F (2, 103) 
=45.64, p<0.001]. Furthermore, there was a higher prevalence of flat and ascending cortisol profiles 
in patients with moderate-to-severe breathlessness (23.4%) compared to healthy controls (0%). The 
only variable which correlated significantly with DCS was MRC dyspnoea grade (rs=0.29, p<0.05). 
These findings suggest that patients with moderate-to-severe breathlessness have evidence of HPA 
axis dysregulation and that this dysregulation may be related to the functional disability imposed by 
breathlessness.  
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Salivary diurnal cortisol profiles in patients 
suffering from chronic breathlessness receiving 
supportive and palliative care services: a cross-
sectional study 
 
1 Introduction 
Chronic breathlessness is a common symptom of advanced cardiorespiratory disease, affecting >90% 
of people with advanced COPD, >60% of people with advanced heart disease and 10-70% of people 
with advanced cancer (Solano et al., 2006). It is a considerable source of psychosocial and physical 
stress, being associated with fear, anxiety, social isolation and functional disability (Booth et al., 
2003). It has also been shown to predict mortality, independent of lung function, in a range of 
conditions, including COPD (Nishimura et al., 2002), pulmonary fibrosis (Nishiyama et al., 2010), and 
older adulthood (Ahmed et al., 2012). These effects suggest a potential role for the stress hormone 
system in the experience of breathlessness.  
The hypothalamic-pituitary-adrenal (HPA) axis is a major regulator of the physiological stress 
response, exerting its effects through its end-hormone, cortisol. Basal cortisol secretion has a 
marked circadian rhythm, characterised by a rapid rise in cortisol secretion upon awakening, 
followed by a fall in cortisol levels throughout the day (Smyth et al., 2013). This pattern becomes 
disrupted in the context of prolonged or repeated exposure to stressful triggers, often manifesting 
as loss or blunting of diurnal variation in cortisol secretion (Miller et al., 2007). Such dysregulation 
has been observed in a wide range of chronic diseases, both malignant (Abercrombie et al., 2004) 
and non-malignant (Hackett et al., 2014), and has been associated with negative disease outcomes 
and characteristics. Flatter diurnal rhythms have been shown to predict mortality secondary to 
cancer (Sephton et al., 2000; Cohen et al., 2012; Sephton et al., 2013) and cardiovascular disease 
(Kumari et al., 2011 ). They have also been associated with more advanced cancer stages (Sephton et 
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al., 2000; Sephton et al., 2013), greater functional disability in cancer (Weinrib et al., 2011; Sephton 
et al., 2013) and worse physical performance in older adulthood (Gardner et al., 2013). 
To date, the relationship of the HPA axis with the physical symptomatology of chronic progressive 
diseases has been explored to a limited degree only. A few studies have described diurnal cortisol 
profiles in relation to fatigue in patients with cancer, but findings have been inconsistent (Sephton et 
al., 2000; Weinrib et al., 2001; Bower et al., 2005, Sephton et al., 2013). One study has identified a 
relationship between HPA axis function and the cancer symptom cluster of pain, fatigue and 
depression, but it did not assess diurnal cortisol rhythmicity (Thornton et al., 2010). Symptoms are 
increasingly understood in the literature to be psychoneurological responses to disease, driven by 
pathophysiological mechanisms which are distinct from, though related to, the underlying 
associated disease (Miller et al., 2008; Dantzer et al. 2012; Kim et al. 2012). It is, thus, important to 
identify these pathophysiological mechanisms to allow therapeutic targeting of symptoms 
independent of disease.  
No studies have examined the relationship between chronic breathlessness and HPA axis function. 
The literature points to a number of specific factors which are suggestive of a link, however. First, 
there is a well-established relationship between breathlessness and anxiety (von Leupoldt et al., 
2011), which might promote a chronic stress response. Second, the perception of breathlessness is 
processed in the same parts of the cortico-limbic system (insula, amygdala and anterior cingulate 
cortex) as other aversive sensations such as pain, hunger and thirst (von Leupoldt et al., 2009), all of 
which are known to activate the stress response. Finally, the aforementioned independent 
relationship between breathlessness severity and mortality, across a range of contexts, is currently 
unexplained; HPA axis dysregulation, in the context of breathlessness, represents one possible 
explanation needing exploration.  
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1.1 Hypothesis, aims and objectives 
We hypothesised that patients suffering from chronic breathlessness due to chronic progressive 
disease would have evidence of HPA axis dysregulation, represented by a flatter diurnal cortisol 
slope. To investigate this, we aimed to measure the salivary diurnal cortisol profile in patients under 
the care of supportive and palliative care services, who were experiencing moderate-to-severe 
disability due to breathlessness, comparing this profile against that of non-breathless patients and 
that of healthy adults. Specific objectives were:  
1) To compare the mean diurnal cortisol slope (slope of the decline in cortisol across the day) in 
patients with moderate to severe breathlessness (Medical Research Council, MRC ≥3), 
against that of non-breathless patients (MRC ≤2) and that of healthy adults.  
2) To compare pre-defined diurnal cortisol slope categories between patients with moderate-
to-severe breathlessness and healthy adults.  
 
2 Material and Methods 
Study procedures for patient participants were approved by the National Research Ethics Service 
Committee, East of England-Norfolk (13/EE/0021). It was part of a larger programme of research, 
registered on the ISRCTN registry (ISRCTN70836126). Study procedures for the healthy control group 
were approved by the ethics committee of the University of Westminster. Written informed consent 
was obtained from all participants prior to enrolment.  
2.1 Participants- patient group (MRC ≥3 and MRC ≤2 subgroups)  
Patients were recruited from a hospital and a hospice in the Cambridgeshire region of the UK.  
Patients from the hospital were recruited via a specialist breathlessness service (Breathlessness 
Intervention Service, BIS), a service delivered by hospital-based personnel to patients living with 
chronic breathlessness in the community. They were considered eligible for the study if they met the 
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referral criteria for BIS: 1) had a diagnosed or investigated cause for breathlessness, 2) were 
troubled by breathlessness despite optimal medical therapy, and 3) might benefit from a self-
management programme. Patients from the hospice were recruited via the day therapy, community, 
and supportive care services, irrespective of whether or not they were breathless. Patients were 
excluded from the study if they: 1) had received systemic steroids within the preceding 4 weeks, 2) 
had asthma or a non-physical cause of breathlessness, 3) were unable to provide informed consent, 
4) were currently receiving inpatient hospital or hospice care, or 5) had rapidly progressive disease 
such that they were imminently dying.  
This recruitment strategy ensured that most of the patients would have advanced disease, that a 
large proportion would be suffering from moderate to severe breathlessness (MRC≥3) and that a 
subsample would not be suffering from breathlessness (MRC≤2).  
2.2 Participants- healthy control group  
The data of participants recruited to a separate study, conducted at the University of Westminster 
(London) (Evans et al., 2007), were used to provide a healthy control group, against which the 
patient group was compared. This group consisted of community-dwelling healthy older adults 
recruited in the South-West London area. Volunteers were excluded from this study if they: 1) were 
receiving steroid medication, 2) had an acute or chronic medical condition, or 3) had evidence of 
cognitive impairment based on the Mini-Mental State Examination.  
2.3 General Procedures 
Study procedures were the same for the patient and healthy control groups, unless stated 
otherwise.  
Demographic and clinical details were obtained through a structured interview, followed by review 
of patients’ clinical records where necessary. All participants were instructed in the study procedures 
and provided with the following study materials: 1) a saliva collection pack consisting of pre-labelled 
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Cortisol Salivette® devices (Sarstedt, Ltd., Leicester), 2) full-written instructions on how to use the 
collection devices, 3) self-recording sheets for documenting the timing of saliva collections, and 4) 
self-administered questionnaires. Upon completion of the study, materials were returned either by 
collection from participants’ homes, by post or upon attendance at a hospice or hospital clinic.  
2.4 Measures 
Salivary diurnal cortisol and demographic variables were assessed for both patients and healthy 
controls. All other measures were obtained for patients only. Questionnaires measuring 
breathlessness, psychological status and sleep were self-administered unless otherwise stated.  
2.4.1 Salivary diurnal cortisol assessment 
Participants were instructed to complete a two-day saliva collection protocol at home, on two 
consecutive weekdays during which nothing out of the ordinary was expected to happen. They 
provided 3 samples per day, synchronised to the time of awakening: 3, 6, and 12 hours after 
awakening.  
Cortisol Salivette® devices consist of a small synthetic swab contained in a sterile plastic 
centrifugation tube. Each plastic tube was pre-labelled with a different instruction about the 
collection day and time relative to awakening (e.g. ‘day 1, 3 hours’; ‘day 2, 6 hours’). Participants 
were instructed to chew on the swab for at least 1 minute and then return it to the tube. They were 
asked to record the time that each sample was collected on a self-recording sheet and were 
instructed to avoid eating, drinking, smoking or brushing their teeth for 30 minutes prior to each 
sample. To avoid mould formation in the Salivette, participants were advised to store their samples 
in their home freezer at the end of each day until postage or collection. At the laboratory, samples 
were stored at -200C until analysis.  
All samples were analysed at the University of Westminster using their standard laboratory 
protocols. Cortisol concentration was determined by Enzyme Linked Immunosorbent Assay (ELISA) 
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developed by Salimetrics LLC (USA), which has the following assay characteristics: standard 
range=0.33-82.77 nmol/l, assay sensitivity= 0.19 nmol/l (lower limit of detection), correlation with 
serum cortisol=0.91 (p<0.0001, n=47 samples). After centrifuging thawed samples at 3500rpm for 10 
minutes, duplicate analysis of samples was undertaken. The intra-assay coefficient of variation was 
<10% for all samples.  
The diurnal cortisol slope (DCS) was calculated for each individual in order to summarise the diurnal 
cortisol profile using the 3-, 6- and 12-hour post-awakening samples. It was first calculated for each 
separate day of collection. After confirming lack of a significant day-difference, an aggregated slope 
across the two days was subsequently calculated by regressing log-transformed cortisol values on 
sample collection time across the two days (6 samples). Using this approach, the slope of the linear 
regression line (unstandardized beta coefficient) represents the diurnal cortisol rhythm (Smyth et al., 
1997; Sephton et al., 2000).  
2.4.2 Demographic and clinical measures 
Demographic data including age, gender and subjective socio-economic status (Adler et al., 2000) 
were recorded for all participants. The following clinical information was obtained for the patient 
group: primary diagnosis, co-morbidities, medication, current use of steroid inhalers, Karnofsky 
Performance Status (Karnofsky and Burchenal, 1949), and Charlson Co-Morbidity Index (Charlson et 
al., 1987).  
2.4.3 Measures of breathlessness 
In view of its multi-dimensional nature, three different measures were used to assess 
breathlessness, each measuring a different dimension.  
2.4.3.1 Medical Research Council (MRC) Dyspnoea Scale 
Perceived functional disability as a result of breathlessness was measured using the Medical 
Research Council (MRC) dyspnoea scale (Fletcher et al., 1959), used with the permission of the 
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Medical Research Council (researcher-administered). Participants were graded from 1 to 5, as 
follows:  
Grade 1: not troubled by breathlessness except with strenuous exercise 
Grade 2: short of breath when hurrying on the level or walking up a slight hill 
Grade 3: walks slower than most people on the level, stops after a mile or so, or stops after 
15 min walking at own pace 
Grade 4: stops for breath after walking around 100 yards or after a few minutes on level 
ground 
Grade 5: too breathless to leave the house, or breathless when undressing  
 
This has been well-validated against other measures of breathlessness and health status in diverse 
cardiorespiratory diseases and has an inter-observer agreement rate of 98% (Mahler and Wells, 
1988; Bestall et al., 1999).  
Consistent with previous studies, the presence of moderate-to-severe breathlessness was defined as 
a MRC dyspnoea grade of ≥3 (Bestall et al., 1999; Ahmed et al., 2012). Thus, the patient group was 
categorised into two clinically distinct subgroups according to MRC dyspnoea grade: 1) MRC 
dyspnoea grade ≤2 (mild or no breathlessness) and 2) MRC dyspnoea grade ≥3 (moderate-to-severe 
breathlessness).  
2.4.3.2 Perceived breathlessness intensity over the past 24 hours 
Perceived breathlessness intensity was measured by asking patients to record how much shortness 
of breath they had experienced ‘over the past 24 hours’ on a numerical rating scale (NRS) of 0 (none) 
to 10 (worst imaginable). The NRS has been shown to be a valid method of measuring present and 
usual breathlessness in patients with chronic respiratory disease (Gift and Narsavage, 1998).   
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2.4.3.3 Mastery domain of the Chronic Respiratory Questionnaire (CRQ)  
Patients’ perceived ability to cope with or ‘master’ their breathlessness with respect to the ‘last 2 
weeks’ was measured using the ‘mastery’ domain of the chronic respiratory questionnaire self-
administered scale (CRQ-SAS) (Guyatt et al., 1987). This domain consists of 4 items, rated on a 7-
point Likert scale from 1 (low mastery) to 7 (high mastery), with overall mastery calculated as the 
mean of the 4 items. It has been shown to be a valid and reliable measure of mastery in COPD 
patients (Cronbach’s alpha=0.83 to 0.88) (Wijkstra et al., 1994). Patients only completed this 
questionnaire if they scored 1 or more on the breathlessness NRS.  
2.4.4 Sleep and psychological measures 
2.4.4.1 Pittsburgh Insomnia Rating Scale-2 (PIRS-2) 
Subjective sleep quality was measured using the 2-item version of the ‘Pittsburgh Insomnia Rating 
Scale (PIRS-2)’, derived from the original 65-item version (Moul et al., 2002). Each item is rated on a 
4-point Likert scale and total scores range from 0 (good) to 6 (poor).  
 
2.4.4.2 Perceived Stress Scale -10 
Perceived stress was measured using the ‘Perceived Stress Scale-10 (PSS-10)’. This is a 10-item 
measure of the degree to which situations in one’s life are perceived as stressful, with reference to 
‘the last month’. Each item is rated on a Likert-type scale and total scores range from 0 (low) to 40 
(high). Validity and internal reliability (Cronbach’s alpha=0.78) have been demonstrated in a US 
population study (Cohen and Williamson, 1988).  
 
2.4.4.3 Hospital Anxiety and Depression Scale (HADS) 
The ‘Hospital Anxiety and Depression Scale (HADs)’ was used to screen for anxiety and depression 
with reference to ‘the past week’. This is a 14-item measure of psychological distress, with separate 
subscales for anxiety (HADs-A: 7-items, 0-21) and depression (HADS-D: 7-items, 0-21). It has been 
shown to be a valid and reliable measure in patient populations (Zigmond and Snaith, 1983).  
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2.4.4.4 Short Warwick-Edinburgh Mental Wellbeing Scale (SWEMWBS) 
Wellbeing was measured using the short-form of the Warwick-Edinburgh Mental Wellbeing Scale 
(SWEMWBS), a 7-item measure of positive mental wellbeing with reference to ‘the last 2 weeks’. 
Each item is rated from 1 to 5 on a Likert-type scale. The total metric score ranges from 7 (low 
wellbeing) to 35 (high wellbeing). Validity and reliability have been demonstrated in a Scottish 
population study (Stewart-Brown et al., 2009).  
 
2.4.5 Measurement of compliance with the salivary cortisol sampling protocol 
Compliance with the protocol for saliva collection was assessed by analysing participants’ self-
reported saliva collection times relative to their self-reported waking time, and assessing whether it 
was consistent with the protocol instructions. In addition, wrist actimeters (Actiwatch 2, Philips 
Respironics, UK) were used to check the accuracy of the self-reported waking time in 38 out of the 
62 patients and in 42 out of the 50 healthy controls. These participants were instructed to apply the 
devices to their wrists the night before saliva collection. Actigraphy data were downloaded and 
analysed using Respironics Actiware version 6.0.4. In line with recommendations from Boyne et al., 
2013, actigraph awakening times were scored by the human eye rather than the computer 
algorithm. The lead researcher scored awakening times and another author verified at least 10% of 
these.  
Participants were considered to have deviated from the protocol if: 1) one or more of their samples 
were collected >1 hour outside the time specified by the protocol (Cohen et al., 2006), or 2) they did 
not record the collection time for one or more samples, or 3) they had one or more missing samples.  
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3 Statistical analysis 
3.1 Mean diurnal cortisol slope with respect to health status 
To investigate our primary hypothesis that the DCS for patients with moderate-to-severe 
breathlessness (MRC ≥3) was different from that for patients with mild/no breathlessness and from 
that of healthy controls, we used a two-stage analysis. First, we calculated the DCS for each patient 
using linear regression of log-transformed cortisol levels against collection time across the 2 days (6 
samples). Second, we assessed whether there was a difference in mean DCS between the three 
study groups (MRC≤2 versus MRC≥3 versus healthy) using ANCOVA, adjusting for age, gender and 
socioeconomic status. Pairwise comparisons were subsequently conducted using unpaired t-tests, 
adjusting for multiple comparisons using the Bonferroni test. ANCOVA model assumptions were 
checked by investigating the distribution of residuals graphically, using histograms and scatterplots.  
For the patient group, in order to explore potential mediators and confounders of the relationship 
between DCS and health status, DCS was further explored in relation to other clinical and 
psychological variables relevant to breathlessness and/or cortisol, using unpaired t-tests for 
categorical variables and correlation for ordinal and continuous variables (Pearson if normally 
distributed and Spearman if non-normally distributed or ordinal).  
All cortisol values were log-transformed to achieve approximately normal distributions. For 
descriptive purposes, raw cortisol data (nmol/L) are used for presentation within tables, summarised 
using both means and standard deviations (SD) and medians and interquartile ranges (IQRs).  
3.2 Diurnal slope categories with respect to health status  
In order to describe the different diurnal cortisol cycle patterns contributing to the mean diurnal 
cortisol slope, individual diurnal cortisol slopes were categorised, using the methodology employed 
by Smyth et al., (1997), as follows: 1) consistent declining, 2) consistent flat, 3) consistent ascending 
or 4) inconsistent. This analysis was limited to the ‘MRC dyspnoea grade ≥3’ and ‘healthy control’ 
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groups due to inadequate numbers in the ‘MRC dyspnoea grade ≤2’ group. The difference in diurnal 
cycle category frequency between the two groups was assessed using a Fisher’s Exact Test.  
The consistency of the slope over the two days was analysed for each individual by comparing the 
slopes for day 1 and day 2. If the absolute difference between the slopes for day 1 and day 2 was 
greater than 0.08 (equivalent to 1 SD from the mean of the day-difference for the group as a whole), 
cycles were categorised as ‘inconsistent’ (Smyth et al., 1997). The value of 0.08 was obtained for the 
SD of the mean day-difference in both the ‘MRC dyspnoea ≥3’ and ‘healthy control’ groups, allowing 
it to be used as the ‘cut-off’ value for both groups. Slopes were also categorised as ‘inconsistent’ if 
the direction of their slopes differed across the two days.  
For individuals categorised as having consistent slopes across the 2 days, an aggregated slope value 
for the 2 days was calculated by regressing the 6 cortisol values over the 2 days on sample collection 
time (Sephton et al., 2000). Based on this value, the consistent slopes were sub-categorised as 
‘declining’, ‘flat’ or ‘ascending’, represented by slopes ≤-0.05, >-0.05, or >0, respectively (Smyth et 
al., 1997).  
3.3 Handling of salivary cortisol protocol deviations 
The DCS was calculated in participants with minor protocol deviations if accommodation could be 
made for these deviations in the slope calculation: 1) in the case of mistimed samples, the actual 
saliva collection times rather than the protocol-stipulated collection times were used in the slope 
calculation, 2) in the case of missing samples, the slope was calculated using the available saliva 
samples, recognizing that a minimum of 2 data points is necessary for slope calculation, 3) where 
sample times were unrecorded, the protocol-stipulated time, as printed on the pre-labelled 
collection tubes, was used. The impact of minor protocol deviations on mean DCS was analysed 
using an unpaired t-test, comparing the mean DCS of fully-compliant participants with that of 
protocol-deviant participants.  
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4 Results 
4.1 Compliance with the saliva collection protocol  
 
In the patient group, of the 366 commissioned saliva samples from 61 patients, 330 (90.2%) were 
collected within 1 hour of the time stipulated by the protocol, 3 (0.8%) were missing and 15 (4.1%) 
had no collection time recorded. In regard to the self-reported awakening time, which was the 
anchor for the subsequent collection times, this was within 15 minutes of the objective actigraphy-
derived awakening time on 78% of the days recorded (n=38).  
Protocol-compliance in the patient group is summarized at a participant-level in Figure 1. Forty-four 
participants (44/61, 72.1%) were compliant for all samples within one hour of the stipulated 
protocol times. Seventeen participants (17/61, 26.2%) had some form of protocol deviation. One of 
these was excluded from data analysis from the outset due to major protocol deviation. The other 
16 participants had evidence of only minor protocol deviation.  
All 16 of the participants with evidence of minor protocol deviation were included in the mean DCS 
analysis, with accommodation made for missing or mistimed samples in the aggregated 2-day slope 
calculation. There was no significant difference in mean DCS between the fully compliant 
participants (n=44; mean DCS=-0.065) and the participants with minor protocol deviations (n=16; 
mean DCS=-0.059; t=0.391, p=0.70), validating the decision to include participants with minor 
protocol deviations in further analyses.  
Compliance for the healthy control group is reported elsewhere (Evans et al. 2007). Due to high 
levels of compliance in this group, all healthy participants were included in the final analysis.   
 
4.2 Demographic, clinical and psychometric characteristics of the samples 
The demographic, clinical and psychometric characteristics for the three study groups are presented 
in Table 1.  
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Across the three groups, there were differences in age, gender and subjective socio-economic 
status. Proportion of females and subjective socioeconomic status were higher in the healthy control 
group, relative to the patient groups. Mean age was lower in the ‘MRC dyspnoea grade ≤2’ group 
relative to the other groups.   
As expected, MRC dyspnoea grade subgroups differed with respect to several clinical and 
psychometric variables. Karnofsky performance status (KPS) and mastery over breathlessness (CRQ 
domain) were higher in those with a MRC grade ≤2, whilst perceived breathlessness intensity (NRS), 
anxiety (HADs-A) and depression (HADs-D) levels were higher in those with a MRC grade ≥3. 
Furthermore, patients with a MRC grade ≤2 had predominantly malignant disease (81.8%), whereas 
patients with a MRC grade ≥3 had predominantly non-malignant disease (71.4%). Self-reported 
saliva collection protocol compliance rate was similar across MRC dyspnoea grade subgroups.  
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Table 1. Demographic, clinical and psychometric characteristics of the three study groups 
 MRC dyspnoea 
grade ≥3  
(n=49) 
MRC dyspnoea 
grade ≤2 
(n=11) 
Healthy 
control 
(n=50) 
 N (%) N (%) N (%) 
Gender (male) 29 (59.2) 4 (36.4) 16 (32.0) 
Site (hospital) 38 (77.6) 2 (18.2) - 
Malignant disease  14 (28.6) 9 (81.8) - 
Main diagnosis:  
COPD  
COPD and other cardiopulmonary disease 
Primary lung cancer alone 
Chronic heart failure alone 
Pulmonary fibrosis (1o or 2o) 
Metastatic cancer (non-lung primary) 
Neuromuscular disease  
Haematological malignancy  
Other pulmonary diseases  
 
11 (22.4) 
8 (16.3) 
8 (16.3) 
7 (14.3) 
5 (10.2) 
5 (10.2) 
3 (6.1) 
0 
2 (4.1) 
 
0 
0 
1 (9.1) 
0 
0 
6 (54.5) 
2 (18.2) 
2 (18.2) 
0 
- 
 
 
 
 
MRC Dyspnoea grade (G1-5):  
 
 
G3: 10 (20.4) 
G4: 19 (38.8) 
G5: 20 (40.8) 
 
G1: 4 (34.4) 
G2: 7 (63.6) 
 
- 
Charlson Co-Morbidity Index  
0-1 
2-3 
4-5 
6-7 
>8 
 
18 (36.7) 
14 (28.6) 
7 (14.3) 
6 (12.2) 
4 (8.2) 
 
1 (9.1) 
4 (36.4) 
0  
5 (45.5) 
1 (9.1) 
- 
Smoking History: 
Never Smoker 
Ex-smoker 
Current smoker  
 
6 (12.2) 
41 (83.7) 
2 (4.1) 
 
6 (54.5) 
5 (45.5) 
0  
- 
 
Oxygen therapy:  
No 
SBOT 
LTOT 
 
35 (71.4) 
8 (16.3) 
6 (12.2) 
 
11 (100) 
0 
0 
- 
Relevant medications:  
None 
Steroid-based inhaler only  
Other† 
Steroid-based inhaler and other  
 
11 (22.4) 
14 (28.6) 
11 (22.4) 
11 (22.4) 
 
4 (36.4) 
1 (9) 
5 (45.5) 
1 (9) 
- 
Relevant medical information:  
Type I or II diabetes mellitus (yes) 
Past/present psychiatric diagnosis (yes) 
Systemic corticosteroids past year (yes) 
 
8 (16.3) 
5 (10.2) 
23 (46.9) 
 
2 (18.2) 
1 (9.1) 
4 (36.4) 
- 
Protocol compliance (yes)‡ 35 (71.4) 9 (81.8) - 
 Mean (SD) Mean (SD) Mean (SD) 
Age  74.92 (8.26) 65.00 (9.14) 73.98 (6.96) 
Subjective SES ladder (1-10) 5.71 (1.74) * 6.36 (1.43) 7.00 (1.76) 
KPS (10-100) 67.14 (9.57) 80.00 (7.75) - 
Breathlessness NRS (0-10) 5.84 (2.36) 1.18 (1.40) - 
CRQ-Mastery (1-7) 4.35 (1.29) 6.04 (0.68)** - 
PSS-10 (0-40) 18.37 (6.84) 13.64 (8.98) - 
HADS-A (0-21) 7.8 (4.30) 4.64 (4.88) - 
HADS-D (0-21) 7.73 (3.33) 4.55 (2.54) - 
SWEMWBS (7-35) 22.46 (4.10) * 23.99 (3.34) - 
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PIRS-2 (0-6) 3.00 (1.86) * 2.36 (1.69) - 
Abbreviations: MRC, Medical Research Council; SBOT, short-burst oxygen therapy; LTOT, long-term oxygen 
therapy; CBIS, Cambridge Breathlessness Intervention Service; SES, socioeconomic status; KPS, Karnofsky 
Performance Status; NRS, numerical rating scale; CRQ, Chronic Respiratory Questionnaire; PSS-10, Perceived 
Stress Scale-10 item version; HADS-A, Hospital Anxiety and Depression Scale- Anxiety domain; HADS-D, 
Hospital Anxiety and Depression Scale- Depression domain; SWEMWBS, Short Warwick-Edinburgh Mental 
Wellbeing Scale; Pittsburgh Insomnia Rating Scale 2-item version. Symbols: †Other relevant medications: anti-
depressants, hormone therapy, opioids, immunosuppressant therapy, chemo-radiotherapy, anti-psychotics 
and insulin; ‡all samples taken within one-hour of the protocol time (self-reported); *n=48, missing data from 
1 participant; **n=6, only completed by those with a score >0 for breathlessness NRS 
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4.3 Mean diurnal cortisol slope with respect to health status 
Salivary cortisol values ranged from 0.10 to 47.31 nmol/l across the three groups. Log-transformed 
cortisol profiles for the three study groups are summarised in Figures 2 and 3. Mean and median raw 
cortisol values for each time point, as well as mean and median DCS, are presented within Figure 2.   
A one-way between-subjects ANCOVA, adjusting for age, gender and socioeconomic status,  
demonstrated a significant main effect of study group (3 levels: MRC≤2, MRC≥3, and healthy control) 
on DCS [F (2, 103)=45.64, p<0.001, 2 =0.47 ], with this model explaining 51.1% of the variability in 
DCS (adjusted R2 =0.511) and study group explaining 47% of the variability in DCS (See Table 2).  
 
Table 2 One-way between-subjects ANCOVA for diurnal cortisol slope by study group (MRC≥3 Vs 
MRC≤2 Vs healthy), with age, gender and socio-economic status as covariates* 
Source df MS F p-value Β coefficient (95% CI) 
Study group 2 0.117 45.636 0.000 MRC≥3: 0.107 (0.085, 0.129) 
MRC≤2: 0.048 (0.012, 0.084) 
Healthy control: 0  
Gender 1 3.232E-5 0.013 0.911 0.001 (-0.02, 0.22)  
Age 1 0.001 0.510 0.477 0.000 (-0.001, 0.002) 
Socio-economic status 1 0.002 0.674 0.413 -0.002 (-0.008, 0.003) 
Intercept 1 0.014 5.494 0.002 -0.183 (-0.299, -0.066) 
Residual  103 0.003    
*Note: R2=0.534 (adjusted R2=0.511), p<0.001; adjustments based on the following covariate values: age=73.5 
and socio-economic status=6.367; Abbreviations: df, degrees of freedom; MS, Mean Squares; CI, Confidence 
Interval 
 
Post-hoc pair-wise comparisons, adjusting for multiple comparisons using the Bonferroni test, 
showed that there was a significant difference in mean DCS between each of the three groups. The 
mean DCS for the MRC≥3 group was significantly flatter than that of the MRC ≤2 group and that of 
the healthy control group (p<0.001 for both comparisons). Furthermore, the DCS in the MRC ≤2 
group was significantly flatter than that of the healthy control group (p=0.024).  
Further subgroup analysis for the patient group indicated that there was no significant difference in 
mean DCS between subgroups when categorised according to steroid inhaler use, systemic 
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corticosteroid history, disease category (malignant versus non-malignant) and study site (see Table 
3a). Furthermore, apart from MRC dyspnoea grade, DCS did not correlate significantly with any of 
the clinical and psychological variables known to be related to breathlessness and/or stress (see 
Table 3b).  
The results of additional statistical analyses, not described here, may be found in the Appendix.  
Table 3: Relationship of the diurnal cortisol slope (DCS) with other clinical and psychological 
variables in the patient group, with a) showing the mean DCS in relation to different subgroup 
characteristics and b) showing the correlation of DCS with continuous and ordinal variables 
a) Mean DCS (SD) by subgroup characteristic* 
 Yes No Statistical difference 
Steroid inhaler  -0.058 (0.043) -0.067 (0.060) t=0.629, p= 0.53 
N=27 N=33  
Systemic corticosteroids in the 
past year  
-0.062 (0.045) -0.064 (0.059) t=0.091, p=0.93 
N=27 N=33  
Malignant disease  -0.075 (0.060) -0.055 (0.047) t=1.46, p=0.15 
N=23 N=37  
Hospital site  -0.055 (0.044) -0.079 (0.066) t=1.46, p=0.16† 
N=40 N=20  
*Two-tailed unpaired t-tests conducted to compare means between subgroups, with equal variances assumed unless 
otherwise stated; †equal variances not assumed (Welch’s t-test) 
 
 
b) Correlation of the DCS (and MRC dyspnoea grade) with other variables† 
 
  MRC  
dyspnoea 
grade 
Breath-
lessness 
NRS  
CRQ-
Mastery 
PSS-
10 
HADS
-A 
HADS
-D 
PIRS-
2 
SWEM
-WBS 
KPS CCI 
DCS r 
p 
N  
0.29 (rs) 
0.027 
60 
0.23 
0.074 
60 
-0.15 
0.27 
55 
0.072 
0.58 
60 
0.087 
0.51 
60 
0.18 
0.17 
60 
0.20 
0.14 
59 
0.074 
0.58 
59 
-0.23 
0.082 
60 
-0.002 (rs) 
0.99 
60 
MRC  
Dyspnoea 
grade 
rs 
p 
N 
1 
- 
60 
0.59 
<0.001 
60 
-0.45 
<0.001 
55 
0.36 
0.005 
60 
0.29 
0.026 
60 
0.35 
0.006 
60 
-0.03 
0.84 
60 
-0.29 
0.029 
59 
0.75 
<0.001 
60 
-0.24 
0.060 
60 
†r=Pearson correlation coefficient; rs=Spearman Rho coefficient (used where variable is not normally distributed); p=two-
tailed significance test; N=sample number. Abbreviations: DCS, diurnal cortisol slope; MRC, Medical Research Council; NRS, 
numerical rating scale; CRQ, Chronic Respiratory Questionnaire; PSS-10, Perceived Stress Scale-10; HADS-A, Hospital Anxiety 
and Depression Score-Anxiety subscale; HADS=D, Hospital Anxiety and Depression Score-Depression subscale; PIRS-2, 
Pittsburgh Insomnia Rating Scale-2; SWEMWBS, Short Warwick-Edinburgh Mental Wellbeing Scale; KPS, Karnofsky 
Performance Status; CCI, Charlson Comorbidity Index 
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4.4 Description of diurnal cortisol slope categories with respect to health status  
The DCS category analysis was confined to patients with a MRC dyspnoea grade ≥3 (n=47). Two 
patients were excluded as it was not possible to calculate their slope on each of days 1 and 2, a pre-
requisite for this analysis.    
There was a significant difference between patient (MRC dyspnoea ≥3) and healthy groups in 
relation to the frequency of the four diurnal cycle categories (Fisher’s exact test=16.337, p<0.001), 
with a higher frequency of aberrant profiles (flat, ascending or inconsistent) in the ‘MRC dyspnoea 
≥3’ group (See Figure 3). In the patient group, the proportions of descending, flat, ascending and 
inconsistent profiles were 48.9%, 19.1%, 4.3% and 27.7% respectively. By contrast, in the healthy 
group, 80% had descending profiles, no participant had a flat or ascending profile and 20% had 
inconsistent profiles.  
 
5 Discussion 
We have described the salivary diurnal cortisol profile, a surrogate marker of HPA axis activity, in 
patients suffering from moderate-to-severe breathlessness (MRC ≥3) secondary to a range of 
cardiorespiratory diseases. We have shown that patients with moderate-to-severe breathlessness 
had significantly flatter diurnal cortisol slopes compared to healthy adults. We have also shown that 
patients with moderate-to-severe breathlessness had a mixture of declining, flat and ascending 
slopes, a pattern significantly different to that seen in the healthy adult group. Furthermore, we 
have shown that patients with moderate-to-severe breathlessness had significantly flatter slopes 
compared to patients with mild/no breathlessness (MRC≤2). Of the many clinical and psychological 
variables measured, MRC dyspnoea grade was the only variable significantly associated with DCS, 
with a higher MRC dyspnoea grade being associated with a flatter DCS.  
Richella Ryan 
23 
 
5.1 Relationship between DCS and disease 
Our study has shown that both patient subgroups (breathless and non-breathless) had significantly 
flatter slopes compared to the healthy control group, after controlling for differences in age, gender 
and socio-economic status.  The finding of flatter diurnal slopes in a patient population is consistent 
with the literature. For example, flatter slopes have previously been reported in specific disease 
groups, including metastatic breast cancer (Abercrombie et al., 2004) and diabetes mellitus (Hackett 
et al., 2014), relative to healthy controls. To the authors’ knowledge, this is the first time that flatter 
slopes have been identified in a mixed patient population, where the patient groups were defined 
according to symptoms rather than underlying disease.  
The mean DCS was markedly flatter in patients with moderate-to-severe breathlessness (MRC≥3) in 
comparison with the healthy control group. Given that the mean DCS for the healthy control group is 
comparable with slope magnitudes reported for other healthy populations in the literature (Stone et 
al., 2001; Ice et al., 2004; Kumari et al., 2011 ), it is reasonable to conclude that the substantially 
flatter mean slope in the breathless patient group points to HPA axis dysregulation. In our study, this 
flatter mean DCS appears to be due to the combined effect of lower 3-hour and higher 12-hour 
cortisol values within patients. It is also consistent with the higher prevalence of flat/ascending 
profiles in this sample relative to the healthy control group.  
In the patients with moderate-to-severe breathlessness, the proportions of descending, flat, 
ascending and inconsistent profiles were 48.9%, 19.1%, 4.3% and 27.7% respectively. To date, the 
different types of cortisol profile patterns that exist within patient populations have not been well-
described. Furthermore, meaningful comparison between the few available studies is virtually 
impossible in the absence of agreed classification and measurement criteria. Sephton et al. (2000) 
categorised 3-day cortisol slopes in patients with metastatic breast cancer (mean age: 52.3 years) 
into three categories, by visual inspection of individual plotted cortisol profiles. They found that 37% 
of patients had declining profiles with an early peak at 08.00am, 49% had late peaks in cortisol at 
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noon or afternoon, and 14% had flat profiles. Though difficult to compare, it is noteworthy that the 
proportion of flat slopes is similar to that in our breathless patient sample. Woods et al. (2008) also 
visually inspected individual cortisol plots in order to categorise 1-day diurnal cycles in patients with 
dementia (2 cohorts, mean age: 81 years). In one cohort (n=21), 52.4% had declining cycles, 14.3% 
had flat cycles, and 33.3% had a rise in the evening cortisol level. In the other cohort (n=16), 43.7% 
had declining cycles, 14.5% had flat cycles, and 35.5% had a rise in the evening cortisol level. These 
are similar to our findings in that only approximately half of the patients had declining cycles. 
5.2 Relationship between DCS and breathlessness 
Our study has also shown that patients with moderate-to-severe breathlessness (MRC ≥3) had 
significantly flatter diurnal cortisol slopes than patients with mild or no breathlessness (MRC ≤2), 
after controlling for age, gender and socioeconomic status. Furthermore, correlational analysis 
indicated that MRC dyspnoea grade was the only clinical variable significantly associated with DCS. 
As MRC dyspnoea grade measures ‘functional disability due to breathlessness’, these findings 
suggest that patients with greater functional disability due to breathlessness have flatter diurnal 
cortisol slopes. It is noteworthy that DCS did not correlate significantly with measures of perceived 
breathlessness intensity (‘breathlessness NRS) or level of mastery over breathlessness (CRQ), though 
there was a trend towards an association with perceived breathlessness intensity. This may suggest 
that DCS is more related to the functional impact of breathlessness rather than its perceptual or 
psychological dimensions.  
Whilst MRC dyspnoea grade measures the functional disability imposed by breathlessness (Bestall et 
al., 1999), the literature suggests that it represents far more than this. For example, it has been 
shown to be related to both disease-specific and generic health-related quality of life in COPD 
patients (Hajiro et al., 1999), and has been shown to be a significant predictor of survival in both 
COPD (Nishimura et al., 2002) and idiopathic pulmonary fibrosis (Nishiyama et al., 2010), 
independent of lung function. It was also shown to be a significant predictor of 2-year and 10-year 
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mortality in a population study of elderly community-dwelling adults, independent of age, gender 
and underlying cardiorespiratory disease (Ahmed et al., 2012). Thus, the association between DCS 
and MRC dyspnoea category could reflect differences in functional impairment, health-related 
quality of life or prognosis between patients with MRC dyspnoea grades ≤2 and grades ≥3. 
In support of our findings, diurnal cortisol rhythm has already been linked to constructs related to 
MRC dyspnoea grade in other populations. The association between flatter diurnal cortisol slopes 
and higher MRC dyspnoea grade is consistent with the growing literature demonstrating flatter 
diurnal slopes in association with shorter survival in cancer (Sephton et al., 2000; Cohen et al., 2012; 
Sephton et al., 2013). It is also consistent with the strong evidence in the literature for a relationship 
between DCS and functional impairment in older adults. In a meta-analysis of 6 adult cohorts (50-92 
years; n=>2000), a larger diurnal drop (difference between morning and evening cortisol) was found 
to be associated with faster walking speed and quicker chair rise, suggesting that smaller diurnal 
drops (or flatter diurnal slopes) are associated with worse physical performance (Gardner et al., 
2013). In keeping with these findings, blunted diurnal variation in cortisol was also shown to be 
associated with greater frailty in a cohort of 200 elderly participants aged 80-90 years (Varadhan et 
al., 2008). 
5.3 Potential mechanisms 
Given the cross-sectional nature of the study, the direction of the relationship between MRC 
dyspnoea grade and diurnal slope cannot be ascertained, and causality cannot be proven. One 
possibility is that HPA axis dysregulation and functional disability due to breathlessness are caused 
by the same underlying disease process. A second possibility is that functional impairment due to 
breathlessness contributes to HPA axis dysregulation.  Alternatively, a third possibility is that HPA 
axis dysregulation, whatever its cause, contributes to functional disability due to breathlessness.  
Chronic systemic inflammation is one process which might explain the relationship between MRC 
dyspnoea grade and diurnal slope, in each of the postulated directions. This process has been 
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identified in many chronic diseases commonly associated with breathlessness, such as COPD (Gan et 
al., 2004) and cancer (Laird et al., 2013). In these contexts, it may contribute to disability due to 
breathlessness (MRC dyspnoea grade) by inducing skeletal muscle atrophy (Cohen et al., 2015). It 
may also contribute to HPA axis dysregulation through excessive stimulation of the HPA axis by 
cytokines, with consequent glucocorticoid resistance (Rosenblat et al., 2014). Furthermore, disability 
due to breathlessness or a high MRC dyspnoea grade may itself promote chronic inflammation, a 
hypothesis supported by the inverse relationship between C-reactive protein and physical activity in 
several population cohort studies (Kasapis and Thompson, 2005), as well as the anti-inflammatory 
effects of exercise in diverse health populations (Nicklas and Brinkley, 2009). Resultant HPA axis 
dysregulation may in turn promote and perpetuate chronic systemic inflammation due to loss of 
effective cortisol-mediated anti-inflammatory effects (Silverman and Sternberg, 2012). 
The negative findings in this study offer valuable insight into potentially relevant mechanisms 
underlying HPA axis dysregulation in this patient group. Counter to our expectations, the DCS was 
not found to be related to any of the psychological variables measured, including depression and 
perceived stress. This is consistent with the findings of other studies of patient populations (Sephton 
et al., 2000; Weinrib et al., 2011; Sephton et al., 2013) and at odds with findings in healthy 
populations where a flatter diurnal slope has been linked with psychosocial stress or chronic stress 
conditions (Ehlert et al., 2001; Adam et al., 2006). This might suggest that the effect of physical 
disease on the HPA axis overrides the effects of psychological factors in the context of advanced 
disease. Furthermore, there was no significant difference in DCS between malignant and non-
malignant subgroups, suggesting that HPA axis dysregulation is a non-specific phenomenon, 
common to a range of disease types, with more research warranted in non-malignant populations. 
Importantly, comparison of DCS between steroid inhaler users and non-users indicated no significant 
difference, suggesting that steroid inhalers did not have a large effect on the diurnal slope in this 
patient population.  
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5.4 Strengths and limitations 
A strength of this study is the analysis and presentation of the DCS both as a continuous variable 
(summarised by the group mean) and as a categorical variable (summarised by slope steepness and 
direction). The mean diurnal slope can hide significant inter-individual variation within a sample. 
Furthermore, a flatter mean diurnal slope may arise for a number of reasons (e.g. a combination of 
descending and ascending slopes), such that it is difficult to interpret its meaning when presented in 
isolation. Using our dual approach, we were able to confidently demonstrate that the flatter mean 
DCS in patients with moderate-to-severe breathlessness was due to a significantly higher proportion 
of flat, ascending and inconsistent slopes in this group compared to the healthy control group. A 
further strength is the consistency of the relationship between MRC dyspnoea grade and DCS, 
regardless of the statistical approach used. A final strength is its novelty in measuring diurnal cortisol 
patterns in patients receiving palliative and supportive care services, a patient group with a 
significant burden of both psychological and physical symptoms; this has allowed further insight into 
the complex mind-body relationship.  
Several limitations must be taken into consideration when interpreting these findings. First, 
compliance with the saliva collection protocol was measured by self-report, such that reported 
compliance may not accurately reflect actual compliance. The wrist actimetry data would suggest 
that self-reporting was reasonably accurate in the majority of cases, however. Secondly, though 
there was no significant difference in mean DCS between the fully compliant participants and the 
participants with minor protocol deviations, the sample size for this subgroup analysis was small; 
thus, we cannot be certain of the impact of minor protocol deviations on the overall results.  
A second limitation was the use of a historical healthy control group, which was recruited through a 
separate study, conducted in a different geographical area; this may have introduced selection bias. 
Despite this, it is important to note that both groups represented community-dwelling older adults 
and that samples from both groups were analysed in the same laboratory using the same assay. 
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Whilst differences in socio-economic status and gender were controlled for in the analysis, potential 
differences in unmeasured psychological variables were not. It is important to bear in mind that the 
DCS appeared to be unrelated to psychological status in the patient group, however, suggesting that 
psychological variables were not important covariates.  
Due to the small sample size, the correlation and subgroup analyses must be interpreted with 
caution. In particular, the comparison between breathless (MRC ≥3) and non-breathless (MRC ≤2) 
patients was limited by the small sample size of the non-breathless subgroup (MRC ≤2; n=11), which 
may not have been a sufficiently representative sample. In addition, in order to reduce patient-
burden, we used a 2-item measure of sleep quality, which is not yet supported by validation studies. 
The small sample size also limited our diurnal slope category analysis, for which we used arbitrary 
cut-off values to define slope categories; a larger sample size may have allowed modelling of diurnal 
profile patterns from the data using a mixed modelling approach. Finally, this analysis is subject to 
the limitations of all case-control analyses in its inability to control for unknown confounders and to 
prove causation.  
5.5 Future work  
There are many questions left to be answered about the relationship of HPA axis function to both 
chronic breathlessness and chronic progressive disease. This study focused on salivary diurnal 
cortisol as a surrogate marker of HPA axis function but it would be important in future studies to 
measure other markers of HPA axis function, such as adrenocorticotrophin hormone (ACTH), to 
assess whether dysfunction occurs at the pituitary or adrenal level. Furthermore, the temporal 
relationship between chronic breathlessness and HPA axis dysfunction needs to be established, as 
well as the impact of disease characteristics such as breathlessness duration, hypoxia and prognosis 
on HPA axis function.  
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6 Conclusion 
In summary, this cross-sectional study provides novel evidence of HPA axis dysregulation in patients 
with moderate-to-severe breathlessness, manifesting as flatter diurnal cortisol decline slopes. The 
degree of dysregulation appears to relate to functional disability due to breathlessness, rather than 
psychological distress. Future longitudinal studies are necessary to explore the temporal relationship 
between breathlessness-induced disability and HPA axis dysregulation, as well as its prognostic 
implications.  
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Appendix:  
One-way between=subjects ANCOVA for diurnal cortisol slope by MRC Dyspnoea category (MRC 
≤2 versus MRC ≥3), controlling for demographic, clinical and psychological covariates* 
Source df MS F p-value 
MRC category  1 0.019 8.055 .007 
Gender 1 0.001 0.620 .435 
Age 1 0.000 0.111 .740 
Socio-economic status 1 0.000 0.068 .795 
Diagnostic Category 1 6.503E-7 0.000 .987 
Karnofsky Performance Status 1 7.737E-5 0.032 .858 
Perceived Stress Scale Score 1 0.000 0.159 .692 
Breathlessness Intensity (NRS) 1 0.001 0.494 .486 
HADS-Anxiety 1 0.001 0.490 .487 
HADS-Depression 1 7.361E-5 0.031 .862 
Intercept 1 0.001 0.571 .454 
Residual  48 0.002   
*Note: R2=0.274 (adjusted R2 = 0.123), p=0.084; Abbreviations: NRS, numerical rating scale; HADS-A, Hospital 
Anxiety and Depression Scale- Anxiety domain; HADS-D, Hospital Anxiety and Depression Scale- Depression 
domain. MRC, Medical Research Council 
 
Participants who returned samples (n=61)
Included despite minor protocol deviation 
(n=16)
-1 missing sample (n=2)
-at least 1 unrecorded collection time (n=3)
-1-2 non-adherent sample times (n=11)
Included in the mean DCS analysis (n=60)
(MRC dyspnoea ≤2, 11; MRC dyspnoea ≥3, 49)
Protocol compliance on both days (n=44) Protocol deviation on one or both days (n=17)
Excluded due to major protocol 
deviation (n=1)
-no collection times recorded and 
1 missing sample, along with 
suspected cognitive impairment 
(n=1)
Figure 1. Summary of protocol compliance for the patient group. Abbreviations: DCS, diurnal cortisol slope; MRC, 
Medical Research Council 
Participants who returned samples (n=61)
Figure 2. Top panel: log-transformed mean salivary cortisol profile over 2 days for each 
participant, with separate graphs (A-C) representing each group. Bottom panel: mean and median 
cortisol concentrations and diurnal slopes per group. 
A. MRC dyspnoea ≥3 (n=49)    B. MRC dyspnoea ≤2 (n=11) C. Healthy control (n=50)
Cortisol 
(nmol/l)
MRC dyspnoea ≥3
(n=49)
mean (SD)
median (IQR)
MRC dyspnoea ≤2
(n=11)
mean (SD)
median (IQR)
Healthy control
(n=50)
mean (SD)
median (IQR)
3-hour 9.82 (8.06)
6.75 (3.95-14.62)
8.88 (3.78)
7.79 (6.19-11.66)
15.35 (8.22)
13.78 (8.34-21.09)
6-hour 8.02 (7.19)
5.47 (2.8-11.63)
5.54 (2.93)
4.89 (3.77-5.55)
8.34 (4.12)
7.24 (5.33-9.84)
12-hour 6.06 (5.97)
3.54 (2.23-7.75)
2.80 (2.80)
2.03 (1.05-3.93)
2.64 (1.45)
2.43 (1.64-3.31)
Diurnal slope 
(lognmol/L/hr)
-0.051 (0.046)
-0.060 (-0.09- -0.02)
-0.117 (0.047)
-0.120 (-0.16- -0.10)
-0.162 (0.054)
-0.160 (-0.19- -0.14)
Figure 3. Boxplot showing the log-transformed cortisol values at 3, 6 and 12 hours after awakening 
for each study group. 
Figure 4. Frequency (% per study group) of the four diurnal cycle categories in the ‘MRC dyspnoea 
grade ≥3’ group versus the ‘healthy control’ group. Cycles were classified as ‘inconsistent’ if the 
diurnal slopes for day 1 and day 2 differed by >0.08. Cycles which were ‘consistent’ (day-difference 
≤0.08) fell into one of 3 other categories: 1) descending (slope≤-0.05), 2) flat (slope>-0.05), or 3) 
ascending (slope>0).
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